Number 3: Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and clinical equivalence to reference denosumab (Prolia/Xgeva), supporting its ...

Richter and Hikma on Thursday announced that the FDA accepted an application for Richter's denosumab biosimilar candidate.

GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of ...

Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat ...

Researchers assessed the therapeutic equivalence of proposed biosimilar CT-P41 and reference denosumab for the treatment of postmenopausal osteoporosis.

GlycoNex developing denosumab biosimilar, SPD8, for the treatment of osteoporosis NEW TAIPEI CITY, Taiwan, Dec. 17, 2024 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter ...

Many people with osteoporosis are unable to tolerate oral bisphosphonates—many others would prefer a six monthly denosumab injection to a once weekly pill that comes with orders to stay upright and ...

Worsening CKD was progressively associated with denosumab-induced hypocalcemia warranting emergency treatment. Denosumab use carries a higher risk for emergency hypocalcemia compared with ...

New Delhi: In line with the proposal presented by Lupin for conducting phase I study of Denosumab 60 mg prefilled syringe solution for injection (60 mg/mL), the Subject Expert Committee (SEC) ...